Actobiotics™ as a novel method for cytokine delivery: The Interleukin‐10 case
L Steidler, P Rottiers, B Coulie - … of the New York Academy of …, 2009 - Wiley Online Library
L Steidler, P Rottiers, B Coulie
Annals of the New York Academy of Sciences, 2009•Wiley Online LibraryInterleukin‐10 (IL‐10) is central in immune downregulation, but so far its use in inflammatory
diseases remains cumbersome. For treatment of inflammatory bowel disease, adequate
amounts of IL‐10 must reach the intestinal lining. Systemic injection of a pharmacologically
active doses of recombinant human (rh) IL‐10 results in very low mucosal levels of protein
and severe toxicity and side effects. In animal models, topical and active delivery of IL‐10 by
ingestion of recombinant Lactococcus lactis (L. lactis) was shown to be a valuable …
diseases remains cumbersome. For treatment of inflammatory bowel disease, adequate
amounts of IL‐10 must reach the intestinal lining. Systemic injection of a pharmacologically
active doses of recombinant human (rh) IL‐10 results in very low mucosal levels of protein
and severe toxicity and side effects. In animal models, topical and active delivery of IL‐10 by
ingestion of recombinant Lactococcus lactis (L. lactis) was shown to be a valuable …
Interleukin‐10 (IL‐10) is central in immune downregulation, but so far its use in inflammatory diseases remains cumbersome. For treatment of inflammatory bowel disease, adequate amounts of IL‐10 must reach the intestinal lining. Systemic injection of a pharmacologically active doses of recombinant human (rh) IL‐10 results in very low mucosal levels of protein and severe toxicity and side effects. In animal models, topical and active delivery of IL‐10 by ingestion of recombinant Lactococcus lactis (L. lactis) was shown to be a valuable alternative. Starting thereof we have developed a novel pharmaceutical platform. Our expertise and TopAct™ (topical and active) delivery technology allows use of recombinant L. lactis– ActoBiotics™– in clinical practice. Here we discuss the development of recombinant L. lactis for intestinal delivery of rhIL‐10 in humans.
Wiley Online Library